Evidence map›Paper›PMID 33184171›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention.

Xiaoling Xu, Mingfeng Han, Tiantian Li, Wei Sun, Dongsheng Wang, Binqing Fu, Yonggang Zhou, Xiaohu Zheng, Yun Yang, Xiuyong Li and 3 more

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.0field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Xiaoling XuRespiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China; ustcwhm@ustc.edu.cn xxlahh08@163.com.
Mingfeng HanRespiratory and Critical Care Medicine, Anhui Fuyang Second People's Hospital, Fuyang 230000, People's Republic of China.ORCID 0000-0001-6646-8085
Tiantian LiRespiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China.
Wei SunRespiratory and Critical Care Medicine, Anhui Fuyang Second People's Hospital, Fuyang 230000, People's Republic of China.
Dongsheng WangRespiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China.ORCID 0000-0002-6409-5366
Binqing FuInstitute of Immunology and the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei 230000, People's Republic of China.ORCID 0000-0002-7713-0001
Yonggang ZhouInstitute of Immunology and the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei 230000, People's Republic of China.
Xiaohu ZhengInstitute of Immunology and the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei 230000, People's Republic of China.
Yun YangIntensive Care Unit, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China.ORCID 0000-0002-2709-6423
Xiuyong LiHemodialysis Center, Anhui Fuyang Second People's Hospital, Fuyang 236000, People's Republic of China.
Xiaohua ZhangRespiratory and Critical Care Medicine, Anhui Fuyang Second People's Hospital, Fuyang 230000, People's Republic of China.
Aijun PanIntensive Care Unit, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China.
Haiming WeiInstitute of Immunology and the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei 230000, People's Republic of China; ustcwhm@ustc.edu.cn xxlahh08@163.com.
University of Science and Technology of China · CNFuyang Second People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedCOVID-19 Drug TreatmentHumansPandemicsSARS-CoV-2Severity of Illness IndexAntibodies, Monoclonal, Humanizedtocilizumab

Identifiers

PMID33184171
PMCPMC7720178
OpenAlexW3102363703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.